Navigation Links
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Date:4/26/2012

reated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment.  The use of Vimpat® in patients with severe hepatic impairment is not recommended. 

For full prescribing information on Vimpat®, visit http://www.vimpat.com/prescribing-information.aspx. (Accessed 18th October, 2011)

For more information on Vimpat®, visit www.Vimpat.com or contact UCB at (800) 477-7877.

Vimpat® (C-V) is a Schedule V controlled substance. 
Vimpat® is a registered trademark under license from Harris FRC Corporation.

Important safety information about Vimpat® in the EU and EEA

Vimpat® (lacosamide) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. Vimpat® solution for infusion is an alternative for patients when oral administration is temporarily not feasible. Contraindications: Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Treatment with Vimpat® has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with Vimpat®  have been observed in clinical studies. Cases with second- and third-degree AV block associated with Vimpat® treatment have been reported in post-marketing experience. Vimpat® should be used with caution in patients with known cond
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Women everywhere know how ... not only uncomfortable, they,re often also embarrassing and have ... Feminine Health Support ( http://ph-defense.com ) is a new, ... an all-natural, homeopathic product. Odor, discharge, ... of vaginal infection. In many cases, the cause of ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... (ASH) Annual Meeting ... Publication Number: 840, ... thromboses (blood clots),and transfusion requirements in patients with a rare ... have,been expected to have less severe disease, according to data ...
... Mich., Dec. 10 CSG/SportsCoatings and,the National Wrestling ... the most proactive and proven method of controlling,bacteria, ... Nationally renowned for its Sports Antimicrobial System (R) ... on all types of,athletic surfaces and fabrics for ...
Cached Medicine Technology:PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 2PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 3PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 4PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 5PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 6PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 7PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 8National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM) 2
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... In its latest blog post, Best Drug ... family close by during a stay in rehab can make ... successful, is highlighting a member of the therapeutic care team ... addicts across the country and around the world: dogs. ... blood pressure, heart rate, and stress levels in recovering addicts,” ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of ... conferences would be beneficial in this [MDL].” Accordingly, the ... the end of December,” the order further provides, “the ... conferences. , “The plain import of this order ... much to be discussed as these cases progress toward ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, ... household chemicals known as phthalates might increase a child,s ... in a new study. Children had nearly an ... 5 and 11 if their mothers were exposed during ... the researchers found. The two phthalates were butylbenzyl phthalate ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... appears higher in non-Hispanic white adolescent girls and young ... in lower socioeconomic areas, according to a report posted ... issue of Archives of Dermatology , one of ... form of skin cancer and represents a substantial cause ...
... , MONDAY, March 21 (HealthDay News) -- A woman,s ... the risk of respiratory problems in her children, according to ... mother,s use of birth control pills may increase the risk ... inconclusive, said the authors of the new study. The ...
... (Mar. 21, 2011) -- A new study published by ... of California, Davis, foresees improvements in patient outcomes after ... technology. A control tower-style telemedicine hub to manage electronic ... boost the likelihood that critically injured victims will get ...
... less likely to refer short girls than short boys ... for their short stature, according to a new study ... medical conditions causing their short stature may go undiagnosed, ... treatment. Researchers from The Children,s Hospital of Philadelphia ...
... during pregnancy is common and is associated with significant ... Despite warnings from the Surgeon General to limit alcohol ... by the National Birth Defects Prevention Study(1) found that ... during their pregnancy, with one-fourth of the women surveyed ...
... Ellin Holohan HealthDay Reporter , SUNDAY, March 20 ... risk of developing diabetes and heart disease, according to a ... four other inflammatory conditions. The study, which looked at ... found higher rates of diabetes and heart illness among asthmatics ...
Cached Medicine News:Health News:Melanoma diagnosis in women associated with higher socioeconomic status 2Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:Health information technology 'control tower' could improve earthquake response 2Health News:Medically underserved girls receive less frequent evaluation for short stature 2Health News:Medically underserved girls receive less frequent evaluation for short stature 3Health News:Adolescent offspring of women who drank alcohol during first trimester 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4
18" Penrose drains...
Provides reliable suction for surgical cases with larger amounts of drainage....
Reliavac® 400cc kits with flat drain, Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Medicine Products: